$2.1 B

ONCE Mkt cap, 20-Sep-2018

$40.9 M

Spark Therapeutics Revenue Q2, 2018
Spark Therapeutics Gross profit (Q2, 2018)40.5 M
Spark Therapeutics Gross profit margin (Q2, 2018), %99%
Spark Therapeutics Net income (Q2, 2018)33.8 M
Spark Therapeutics EBIT (Q2, 2018)-83.5 M
Spark Therapeutics Cash, 30-Jun-2018201.1 M
Spark Therapeutics EV1.9 B

Spark Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

633.9 k22.1 m20.2 m12.1 m

Revenue growth, %

3380%(9%)

R&D expense

16.4 m46 m86.4 m135.2 m

General and administrative expense

7.9 m23.4 m48.1 m111.1 m

Operating expense total

24.2 m69.4 m134.4 m270.6 m

EBIT

(24.3 m)(47.3 m)(125.4 m)(258.5 m)

EBIT margin, %

(3838%)(214%)(621%)(2143%)

Interest income

4.1 m

Pre tax profit

(254.4 m)

Income tax expense

963 k

Net Income

(24.3 m)(47.1 m)(123.7 m)(253.5 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

2.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.5 m15.7 m40.9 m

Cost of goods sold

121 k390 k

Gross profit

15.6 m40.5 m

Gross profit Margin, %

99%99%

R&D expense

8.3 m9.3 m11.8 m18.3 m19.6 m22.4 m32.7 m33 m30.1 m55.6 m

General and administrative expense

3.7 m6.3 m6.5 m8.9 m10.7 m12 m21.4 m26.7 m33.5 m63.2 m

Operating expense total

12 m15.7 m18.3 m27.1 m30.3 m34.4 m54.1 m78.5 m64.6 m124.4 m

EBIT

(9.7 m)(14.4 m)(17 m)(25.8 m)(29 m)(33.1 m)(52.9 m)(77 m)(48.9 m)(83.5 m)

EBIT margin, %

(428%)(1117%)(1301%)(2005%)(2251%)(2543%)(4149%)(5191%)(312%)(204%)

Interest expense

6.1 k

Interest income

11 k51.6 k54.8 k260.4 k333.5 k574.9 k2.2 m4.7 m

Pre tax profit

(76.5 m)(46.4 m)33.8 m

Income tax expense

2.1 m(10 k)(22 k)

Net Income

(9.7 m)(14.3 m)(16.9 m)(25.6 m)(28.7 m)(32.6 m)(52.3 m)(74.4 m)(46.4 m)33.8 m

Spark Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.6 m293.5 m58.9 m96.7 m

Accounts Receivable

244.4 k16.9 m16.8 m

Current Assets

77.4 m311.6 m314.6 m533.2 m

PP&E

12.7 m17 m19.8 m61.7 m

Goodwill

1.2 m1.3 m

Total Assets

90.4 m329.8 m373.9 m616.8 m

Accounts Payable

2.7 m9.7 m9.9 m14.2 m

Short-term debt

302 k312 k

Current Liabilities

15.9 m22.1 m30 m53.7 m

Long-term debt

1.2 m912 k

Total Debt

1.5 m1.2 m

Total Liabilities

43.6 m103.2 m

Additional Paid-in Capital

54.4 m419.8 m584 m1 b

Retained Earnings

(81.6 m)(128.7 m)(252.4 m)(505.9 m)

Total Equity

55.2 m290.5 m330.3 m513.6 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.6 x1.1 x1.1 x1.2 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

234.4 m223 m212.2 m275 m225 m90.6 m27.5 m36.8 m127.7 m201.1 m

Accounts Receivable

669.4 k933.1 k1.3 m812.8 k1.2 m1 m5.9 m5 m

Inventories

5.6 m12.7 m

Current Assets

235.9 m225.1 m214.3 m277.8 m335.3 m309.2 m263.4 m226.3 m621 m691.6 m

PP&E

13.4 m13.5 m14.2 m18.4 m19.6 m19.8 m23.1 m25.5 m62.9 m68.7 m

Goodwill

2.1 m2.1 m2.1 m1.1 m1.2 m1.3 m1.2 m

Total Assets

249.7 m239 m228.9 m314.9 m420.3 m399.5 m335.1 m276.6 m687.7 m773.5 m

Accounts Payable

3.1 m4 m6.2 m7.2 m6.8 m8.6 m14 m15.1 m15.2 m8.8 m

Short-term debt

275 k304.5 k307 k315 k317 k

Current Liabilities

11.2 m13.4 m18.6 m18.2 m18.6 m24.1 m29.7 m37.2 m54.6 m37.4 m

Long-term debt

1.3 m1.1 m1.1 m832 k752 k

Total Debt

1.6 m1.5 m1.4 m1.1 m1.1 m

Total Liabilities

32.7 m33.5 m37.2 m35.8 m34.7 m40 m45.5 m48.5 m208 m189.8 m

Additional Paid-in Capital

308.2 m311.1 m314.2 m434 m569.1 m575.6 m596.4 m607.5 m1 b1.1 b

Retained Earnings

(91.3 m)(105.7 m)(122.6 m)(154.3 m)(183 m)(215.5 m)(304.7 m)(379 m)(557.2 m)(477.1 m)

Total Equity

216.9 m205.5 m191.7 m279.2 m385.6 m359.5 m289.6 m228.2 m479.7 m583.7 m

Financial Leverage

1.2 x1.2 x1.2 x1.1 x1.1 x1.1 x1.2 x1.2 x1.4 x1.3 x

Spark Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(24.3 m)(47.1 m)(123.7 m)(253.5 m)

Depreciation and Amortization

169.8 k1.7 m3.6 m4.9 m

Accounts Receivable

(144.4 k)(16.7 m)(234.8 k)8.9 m

Accounts Payable

2.3 m9.1 m10 m13 m

Cash From Operating Activities

10.4 m(47.5 m)(80.4 m)(154.5 m)

Purchases of PP&E

(11.7 m)(4.5 m)(8.5 m)(9.7 m)

Cash From Investing Activities

(11.7 m)(4.5 m)(285.5 m)(207.7 m)

Long-term Borrowings

(24.6 k)(302 k)

Cash From Financing Activities

75.9 m271 m131.4 m400.3 m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(9.7 m)(24.1 m)(41 m)(25.6 m)(54.3 m)(86.8 m)(52.3 m)(126.6 m)(46.4 m)33.8 m

Depreciation and Amortization

370.6 k797.2 k1.2 m744.1 k1.7 m2.6 m1 m2.2 m1.5 m3.1 m

Accounts Receivable

15.7 m15.6 m15.5 m10.7 m11.7 m

Inventories

(5.6 m)(12.7 m)

Accounts Payable

870.4 k3.2 m7.7 m(1.1 m)(2 m)4.2 m(2.7 m)4.8 m(8.4 m)(8 m)

Cash From Operating Activities

(8.9 m)(19.3 m)(29.7 m)(7.7 m)(31.1 m)(51.8 m)(33.1 m)(75.9 m)53.4 m6.9 m

Purchases of PP&E

(1.7 m)(2.5 m)(3.1 m)(4.5 m)(5.7 m)(7.5 m)(2.2 m)(7.2 m)(4.1 m)(8.1 m)

Cash From Investing Activities

(1.7 m)(2.5 m)(3.1 m)(10.4 m)(165.5 m)(281.4 m)(1.7 m)49.2 m(22.7 m)87.9 m

Long-term Borrowings

(24.6 k)(74.6 k)(149.8 k)(77 k)(155 k)

Cash From Financing Activities

170.5 m170.3 m170.4 m(461.2 k)128.1 m130.3 m3.4 m4.5 m261 k9.6 m

Spark Therapeutics Ratios

USDY, 2018

EV/EBIT

-23.3 x

EV/CFO

284.2 x

Financial Leverage

1.3 x
Report incorrect company information

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Report incorrect company information